“As I said in Marburg, the Pan-African Vaccine Manufacturing Project fits perfectly with Ghana’s roadmap for domestic vaccine development and manufacturing. Ghana is ready to play her role, and I reaffirm, once again, her determination to make the project work successfully.”
These were the words of the President of the Republic, Nana Addo Dankwa Akufo-Addo, at the groundbreaking ceremony for the commencement of construction of a vaccine manufacturing plant in Kigali, Rwanda, on Thursday, 23rd June 2022.
Expressing his gratitude to President Paul Kagame for the invitation to participate in the event, President Akufo-Addo indicated that the commencement of construction “signals to the rest of the world the commencement of this end-to-end vaccine manufacturing facility, involving Rwanda, Senegal and my own country of Ghana.”
In his remarks, the President indicated that the import of the Pan-African Project means that Ghana, Senegal, and Rwanda must work together, the reason why the relationship between the Food and Drugs Authorities (FDA) of Ghana and Rwanda is being deepened with the signing of a new Memorandum of Understanding on Friday, 24th June.
“Through this, FDA Ghana, which achieved WHO Global Benchmarking Maturity Level Three (3) in 2020, and is working hard to achieve Maturity Level Four (4) by the end of this year, will assist FDA Rwanda to attain WHO Maturity Level Three (3) as soon as possible. Both agencies will collaborate further in vaccine drug product manufacturing, fill, finish and lot release in their respective countries,” he said.
President Akufo-Addo continued, “Again, a collaboration between our two countries resulted recently in a team from Rwanda visiting research institutions in Ghana, to strengthen institutional development and partnership towards vaccine discovery and advancement”.
In addition, the President revealed that Ghana’s research institutions are undergoing capacity-building to be ready for the discovery and development of vaccines and other biologicals, stating that “a consortium of Ghanaian pharmaceutical companies, led by DEKS Vaccines Ltd., is working closely with BioNTech Rwanda, BioNTech Germany, and kENUP to fill, finish and package the drug product in Ghana from the plant here in Rwanda.”
He thanked BioNTech of Germany, the kENUP Foundation, IFC, EIB, and the other financial institutions for working closely together with African countries to enable the continent to achieve vaccine self-sufficiency.
“I assure all and sundry that Ghana is delighted to be part of this Pan-African Project to manufacture mRNA COVID, Malaria, and TB vaccines from drug substance through drug product to fill, finish and package,” the President added.